ALTIMMUNE, INC. Adjustments to Additional Paid in Capital, Warrant Issued
ALTIMMUNE, INC. (ALT) reported Adjustments to Additional Paid in Capital, Warrant Issued of $30.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-12
- ALTIMMUNE, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-06-30 was $30.30M.
- ALTIMMUNE, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2017-12-31 was $0.00.
- ALTIMMUNE, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2017-03-31 was $548.96K.
- ALTIMMUNE, INC. adjustments to additional paid in capital, warrant issued for fiscal 2017 was $548.96K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|
| 2026-06-30 | $30.30M 10-Q · filed 2026-08-12 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $548.96K 10-K · filed 2019-04-01 | |
| 2017-09-30 | $548.96K 10-Q · filed 2017-11-09 | ||
| 2017-03-31 | $548.96K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |